Author: Elena Morales

  • Chronic Lower Back Pain Market Size Scale at USD 6.12 Billion by 2033

    The chronic lower back pain market was valued at US$ 2.46 billion in 2023 and is predicted to reach US$ 6.12 billion by the end of 2033, representing an impressive CAGR of 9.52% from 2024 to 2033. The increasing geriatric population with arthritis is one of the leading causes of chronic lower back pain, which is driving the market’s growth.

    Chronic Lower Back Pain Market Revenue 2023 - 2033

    Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5156

    Key Takeaways/ Important Points to Note

    • North America has held a largest revenue share of 48.12% in 2023.
    • By drug class, the non-steroidal anti-inflammatory drugs segment has contributed more than 26% of revenue share in 2023.
    • By drug class, the opioids segment held the second-largest share of the market and is expected to grow at the fastest rate during the forecast period.
    • By route of administration, the oral segment dominated the chronic lower back pain market in 2023.
    • By route of administration, the topical segment is growing significantly in the market.
    • By distribution channel, the retail & online segment dominated the chronic lower back pain market in 2023.

    Industry at a Glance

    The chronic lower back pain market deals with all the aspects associated with chronic lower back pain, which includes research & development, development of medication, disease monitoring, treatment, and post-treatment care. Even after an original injury or underlying cause of acute low back pain has been addressed, lower back pain that persists for more than 12 weeks or three months is referred to as chronic low back pain (CLBP). In the past ten years, the frequency of CLBP in adults has climbed by over 100%, and as the population ages, it will continue to rise sharply, impacting men and women of all ethnic backgrounds. Some of the main reasons for lower back pain are age, smoking, heredity, degree of fitness, weight increase, and occupational variables, in addition to mental health issues. Healthcare facilities, drug manufacturers, pharmacies, academic institutions, research centers, and assisted living facilities all play a role in the expansion of the chronic lower back pain market.

    Top Companies of the Chronic Lower Back Pain Market

    • SpineThera Inc. (U.S.)
    • Pfizer Inc (U.S.)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Johnson & Johnson Private Limited (U.S.)
    • Medtronic (Ireland)
    • Endo Pharmaceuticals Inc. (Ireland)
    • Sanofi (France)
    • Merck & Co Inc. (U.S.)
    • Koninklijke Philips N.V. (Netherlands)
    • Vertebral Technologies, Inc. (U.S.)
    • Boston Scientific Corporation (U.S.)
    • Dr. Reddy’s Laboratories Ltd. (India)
    • Astellas Pharma Inc. (Japan)
    • CELGENE CORPORATION (U.S.)

    Segments Covered in Chronic Lower Back Pain Market Report

    By Drug Class

    • Non-steroidal Anti-inflammatory Drugs
    • Antidepressants
    • Analgesic
    • Opioids
    • Others

    By Route of Administration

    • Oral
    • Topical
    • Others

    By Distribution Channel

    • Hospital Pharmacies
    • Retail & Online Pharmacies

    By Region

    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field –  https://www.towardshealthcare.com/table-of-content/chronic-lower-back-pain-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5156

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Chronic Obstructive Pulmonary Disease (COPD) Market Size (USD 33.29 Bn) by 2033

    The chronic obstructive pulmonary disease market size was valued at US$ 21.6 billion in 2023 and is predicted to reach US$ 33.29 billion by the end of 2033, representing an impressive CAGR of 4.42% from 2024 to 2033.

    Chronic Obstructive Pulmonary Disease Market Revenue 2023 - 2033

    Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5154

    Key Takeaways

    • By region, North America dominated the chronic obstructive pulmonary disease market in 2023.
    • By region, Asia Pacific is estimated to grow at the fastest rate during the forecast period.
    • By disease type, the chronic bronchitis segment dominated the market in 2023.
    • By treatment type, the drugs segment dominated the market in 2023.
    • By treatment type, the oxygen therapy segment is expected to grow at the fastest rate during the forecast period.
    • By end-user, the hospital & clinics segment dominated the market in 2023.

    Industry at a Glance

    The chronic obstructive pulmonary disease market revolves around all the aspects associated with COPD, which are research & development, drug development, process development, diagnosis, treatment, monitoring, and post-treatment care. Chronic obstructive lung disease, or COPD, is a common lung disorder that reduces airflow and causes breathing difficulties. COPD patients may develop lung damage or phlegm accumulation. The symptoms include coughing, wheezing, exhaustion, and sometimes even phlegm.

    Tobacco and air pollution are the two primary causes of COPD. While there is no known treatment for COPD, a person’s symptoms may improve if they give up smoking, shield themselves from air pollution, and become immunized to ward against infections. It can also be treated with oxygen, drugs, and pulmonary rehabilitation. Because chronic obstructive pulmonary disease cannot be cured and needs ongoing medication, therapy, and monitoring, the market for this condition is always expanding. The growing prevalence is also increasing due to the high amount of smoking, pollution, and occupational hazards.

    Top Companies of the Chronic Obstructive Pulmonary Disease Market

    • Almirall
    • Abbott Laboratories
    • Dr. Reddy’s Laboratories Ltd.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline
    • Boehringer Ingelheim
    • Pfizer Inc.
    • Astellas Pharma
    • Novartis AG
    • Merck & Co., Inc.

    Segments Covered in the Chronic Obstructive Pulmonary Disease Market Report

    Disease Type

    • Emphysema
    • Chronic Bronchitis

    Treatment Type

    • Drugs
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy

    End User Type

    • Hospitals & Clinics
    • Homecare Settings
    • Others

    Region

    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Rest of Asia-Pacific
    • Rest of the World

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field –  https://www.towardshealthcare.com/table-of-content/chronic-obstructive-pulmonary-disease-market-sizing 

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5154

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Non-Small Lung Carcinoma Market Size Boost at USD 21.51 Billion by 2033

    The non-small lung carcinoma market was valued at US$ 8.27 billion in 2023 and is predicted to reach US$ 21.51 billion by the end of 2033, representing an impressive CAGR of 10.03% from 2024 to 2033. Clinical research, development of new treatment options, and prevalence of NSCLC is driving the growth of the market.

    Non-Small Lung Carcinoma Market Size 2023 - 2033

    Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5155

    Key Takeaways

    • By region, North America dominated the non-small lung carcinoma market in 2023, and it is expected to remain dominant during the forecast period.
    • By region, Asia Pacific is estimated to grow at the fastest CAGR during the forecast period of 2024-2033.
    • By type, the adenocarcinoma segment dominated the market in 2023.
    • By type, the squamous cell cancer segment is expected to grow at the fastest CAGR during the forecast period.
    • By treatment, the targeted therapy segment dominated the market in 2023.
    • By treatment, the immunotherapy segment is expected to grow significantly during the forecast period.
    • By distribution channel, the hospital pharmacy segment dominated the non-small lung carcinoma market in 2023.

    Industry at a Glance

    Non-small cell lung cancer (NSCLC) is the most common type. Around 85% of lung cancer cases are NSCLC. This illness is caused by cancer cells found in lung tissue. While NSCLS progresses more slowly than small-cell lung cancer, it often has spread to other parts of the body by the time it is detected. Timely diagnosis and treatment are of utmost importance. The non-small lung carcinoma market is growing due to the increasing prevalence of lung cancer. The major cause of lung cancer is smoking, and other factors that contribute to NSCLC are air pollution, industrial substances, radiation exposure and tuberculosis. Early detection and treatment of NSCLC are needed.

    Laboratory tests, chest X-rays, CT scans, biopsy, sputum cytology, bronchoscopy, thoracoscopy and thoracentesis are some of the diagnoses and tests that need to be done, which drive the growth of the non-small lung carcinoma market. Furthermore, treatment, medications, hospital admission, continuous monitoring, and post-treatment recovery are involved after diagnosis. With time, the cases of NSCLC are increasing; hence, the need for all the tests, treatments, monitoring and other procedures will continue to increase.

    Top Companies of the Non-Small Lung Carcinoma Market

    • Eli Lilly and Company
    • Celgene Corporation
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Sanofi, Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.

    Segments Covered in Non-Small Lung Carcinoma Market Report

    By Type

    • Squamous Cell Carcinoma
    • Large Cell Carcinoma
    • Adenocarcinoma
    • Others

    By Treatment Type

    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy

    By Distribution Channel

    • Hospital Pharmacy
    • Drug Store and Retail Pharmacy
    • Online Pharmacy

    By Region

    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/non-small-lung-carcinoma-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5155

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Cancer Vaccines Market Size Climb at USD 30.16 Billion by 2033

    The cancer vaccines market was valued at US$ 10.21 billion in 2023 and is predicted to reach US$ 30.16 billion by the end of 2033, representing an impressive CAGR of 11.44% from 2024 to 2033. The increasing prevalence of cancer, research and development and continuous efforts taken by governments and key stakeholders drive the market’s growth.

    Cancer Vaccines Market Size 2023 - 2033

    Click here to uncover hidden insights @ https://www.towardshealthcare.com/download-statistics/5153

    Key Takeaways:

    • North America has held the largest revenue share of 38.40% in 2023.
    • Asia Pacific is expected to witness the fastest growth during the forecast period of 2024-2033.
    • By type, the preventive segment has held a major revenue share of 55% in 2023.
    • By type, the therapeutics segment is expected to grow at the fastest rate during the forecast period.
    • By indication, the cervical cancer segment has contributed more than 31% in 2023.
    • By distribution channel, the hospitals segment dominated the market in 2023 and will continue to dominate during the forecast period.

    Market Overview/Industry at a Glance

    The cancer vaccines market deals with research & development, testing, manufacturing and distribution of cancer vaccines in the healthcare sector. Cancer vaccines are none other than immunotherapies used as a treatment procedure to boost the immune system of cancer patients for fighting against cancer. There are two types of cancer vaccines: therapeutic and preventive. Currently, HPV vaccines and hepatitis B vaccines are two preventive vaccines approved, while prostate cancer vaccines, bladder cancer vaccines, and melanoma vaccines are some of the therapeutic vaccines that are approved by the Food and Drug Administration.

    One of the major reasons for the growth of the market is the increased number of cancer patients due to different factors like lifestyle choices, environmental pollution, genetics, aging, substance abuse, chemical exposure, exposure to sun/UV radiation, and so on. Apart from this, major key players and researchers are continuously making efforts to improve the existing vaccines and develop new vaccines for preventive majors in which the governments are equally participating by providing funds, facilities, and proper infrastructure.

    Top Companies in the Cancer Vaccines Market

    • Generex Biotechnology Corporation
    • Immunocellular Therapeutics, Ltd
    • Vaccinogen, Inc.
    • GlaxoSmithKline plc (GSK)
    • Advaxis Inc.
    • Dynavax Technologies Corporation
    • Merck & Co., Inc.
    • SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION)
    • UbiVac
    • Amgen Inc.

    GlaxoSmithKline plc (GSK) Pipeline

    Company GlaxoSmithKline plc (GSK)
    Headquarters London, UK, Europe
    Pipeline 2023 was a great year for the company, and it is planning to do 12 major launches from 2025, which will include vaccines and specialty medicines related to oncology, HIV, infectious diseases, and respiratory diseases.

    Merck & Co. Inc. Pipeline

    Company Merck & Co. Inc.
    Headquarters New Jersy, United States, North America
    Pipeline Merck and Moderna were working on (MSD)mRNA-4157 vaccine for patients with resected high-risk (Stage IIB-IV) melanoma. After the Approval of the FDA in February 2023, the company entered clinical trial phase III of the vaccine, which included 1089 patients, and the study will be concluded by 2029.

    Increased Cases of Cancer Patients Drive the Market Growth

    In recent years, the number of cancer patients has grown tremendously. Not only the number but also the types of cancers have increased. Certain factors like genetics, exposure to UV radiation, and occupational hazards have been the major contributors to an increased number of cancer patients. However, factors such as increased rates of obesity, processed food consumption, pollution, unhealthy lifestyles, substance abuse, and lack of knowledge & awareness are all contributing to the increased number of cancer patients.

    • According to Cancer Research UK, there are more than 200 types of cancers sub-divided into five categories: carcinoma, sarcoma, leukemia, lymphoma& myeloma, and brain & spinal cord cancers.
    • According to the World Health Organization, cancer is the second leading cause of death worldwide, with 10 million deaths and 20 million new cases. It is estimated that the number will rise by 60% in the next two decades, and by 20240, the number of cancer patients will rise up to 30 million.

    Segments Covered in the Report

    By Type

    • Preventive Cancer Vaccines
    • Therapeutic Cancer Vaccines
    • Others

    By Indication

    • Cervical Cancer
    • Prostate Cancer
    • Other Indications

    By Technology

    • Recombinant Cancer Vaccines
    • Viral Vector and DNA Cancer Vaccines
    • Whole-cell Cancer Vaccines
    • Others

    By Distribution Channel

    • Hospitals
    • Government Suppliers

    By Geography

    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East and Africa

    Read Also: https://www.healthcarewebwire.com/us-home-infusion-therapy-news/

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/cancer-vaccines-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5153

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Multiple Sclerosis Diagnosis and Treatment Market Overview Report (2024 – 2032)

    The multiple sclerosis diagnosis and treatment market size is estimated to grow from USD 22.14 billion in 2023 to reach around USD 30.28 billion by 2032, registering a CAGR of 3.4% between 2024 and 2032.

    Multiple Sclerosis Diagnosis and Treatment Market Size 2023 - 2032

    Click here to uncover hidden insights @ https://www.towardshealthcare.com/download-statistics/5140

    Report Highlights:

    • The role of technology advancements in multiple sclerosis.
    • Distribution of economic burden of multiple sclerosis.
    • Early disease diagnosis helps multiple sclerosis patients with better prevention.
    • Multiple sclerosis related product revenues of different market participants.
    • Relapse-Remitting MS (RRMS) being the most common type, dominated the market in 2023 with over 70% market share.
    • Medications reported a significant 81% of market share in 2023.
    • Asia Pacific is predicted to be the fastest-growing region with 7.0% CAGR over the forecast period.

    In February 2024, Multiple Sclerosis Australia awarded 17 new research grants totaling over $4.5 million for various projects across the country. These grants support different studies and fellowships, lasting from one to five years, all aimed at essential areas of M.S. research.

    Multiple sclerosis is a typical disabling neurological disease. In young adults, symptoms usually appear between 20 and 40.

    Multiple sclerosis develops when immune system cells, which generally defend us against bacteria, viruses, and unhealthy mis, attack central nervous system cells. Myelin is a substance that forms the protective sheath (myelin sheath) surrounding nerve fibers (axons).

    Multiple sclerosis is a chronic disease that impacts individuals differently. A small percentage of people with multiple sclerosis will have a mild course with little to no disability. In contrast, others will have a slowly worsening disease that leads to increased disability over time. Most people with M.S., on the other hand, will experience brief periods of symptoms followed by extended periods of relative of relative passiveness (lack of activity or dormancy) with partial or complete recovery. The disease is rarely fatal, and most M.S. patients have average expectancy.

    There are three main types of multiple sclerosis according to the progression of symptoms over time:

    • Relapsing-remitting Multiple Sclerosis: Symptoms come and go, with periods of recovery in between. This is the most common type.
    • Secondary-progressive Multiple Sclerosis: Symptoms worsen gradually over time after initially having relapses.
    • Primary-progressive Multiple Sclerosis: Symptoms get worse steadily from the start without clear periods of improvement.

    Increased research grants and favorable legislation are adding to the regional market’s growth. For example, in November 2023, the National Multiple Sclerosis Society allocated USD 4 million towards new research initiatives, in line with their strategy outlined in the Pathways to Cure’s roadmap. This investment is part of their annual commitment of over USD 30 million across more than 200 MS research projects worldwide.

    For instance,

    • In June 2022, Bristol Myers Squibb published additional analyses of the Zeposis Phase 3 DAYBREAK open-label extension and SUNBEAM trials. These studies found that early Zeposia use provided cognitive benefits for patients with relapsing from multiple sclerosis.

    Early diagnosis techniques for multiple sclerosis have become increasingly important as they allow for timely treatment and management of the condition. Techniques such as Magnetic resonance imaging, cerebrospinal fluid analysis, and neurological help doctors detect multiple sclerosis in its early stages when symptoms are mild or absent. This early detection improves the patient’s prognosis and increases the demand for treatment options. With advancements in multiple sclerosis treatment, including disease-modifying therapies and symptom management strategies, more people are seeking medical care and support upon receiving a multiple sclerosis diagnosis. This increases the demand for early diagnosis techniques to improve outcomes and enhance the quality of life for individuals living with multiple sclerosis.

    Multiple Sclerosis Diagnosis and Treatment Market Companies

    • Siemens Healthineers AG
    • General Electric Company
    • F. Hoffmann-La Roche Ltd.
    • Biogen Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Sanofi S.A.
    • Bristol Myers Squibb Company
    • Teva Pharmaceutical Industries Ltd.
    • Abbott Laboratories

    Multiple Sclerosis Diagnosis and Treatment Market Segments

    By Type

    • Clinically Isolated Syndrome (CIS)
    • Relapse-Remitting MS (RRMS)
    • Primary Progressive MS (PPMS)
    • Secondary Progressive MS (SPMS)

    By Diagnosis

    • Imaging Tests
    • Spinal Fluid Analysis
    • Other Tests

    By Treatment

    • Medications
      • Injectables
        • Beta Interferons
        • Glatiramer Acetate
      • Oral Medications
        • Fingolimod
        • Dimethyl Fumarate
        • Teriflunomide
        • Cladribine
        • Diroximel Fumarate
        • Siponimod Tablets
      • Infusion Treatments
        • Natalizumab
        • Ocrelizumab
        • Alemtuzumab
        • Mitoxantrone
    • Physical, Occupational or Speech Therapy
    • Mental Health Counselling

    By Geography

    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

    Read Also: https://www.healthcarewebwire.com/us-home-infusion-therapy-market-size/

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field –  https://www.towardshealthcare.com/table-of-content/multiple-sclerosis-diagnosis-and-treatment-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5140

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Healthcare Analytics Market Size, Shares and Trends Report

    The healthcare analytics market size is estimated to grow from 42.90 billion in 2023 to reach around USD 241.16 billion by 2032, registering at a CAGR of 19.1% between 2024 and 2032.

    Healthcare Analytics Market Size 2023 - 2032

    For additional details, click here @ https://www.towardshealthcare.com/download-statistics/5141

    Report Highlights:

    • Software components being largely used dominated the market with a 60% market share in 2023.
    • Clinical applications reported the largest market share with 40% in 2023.
    • Healthcare providers dominated the market in 2023 with a 40% market share.

    In 2021, there was a noticeable surge in demand for Electronic Health Record (EHR) systems, propelled by the growing uptake among office-based physicians. According to data from the Centers for Disease Control and Prevention, 88.2% of office-based physicians were using an EHR system, with 77.8% having a certified system.

    Healthcare analytics involves data analysis tools and techniques to gain insights from healthcare data. It encompasses collecting, processing, and interpreting vast amounts of healthcare-related information to improve decision-making, enhance patient care, and optimize operational efficiency within healthcare organizations. Healthcare analytics helps stakeholders, including healthcare providers, administrators, insurers, and policymakers, make informed decisions by identifying patterns, trends, and correlations within data. This data can come from various sources, such as electronic health records (EHRs), medical imaging, patient demographics, billing records, and clinical trials.

    The importance of healthcare analytics lies in its ability to drive evidence-based decision-making, enabling healthcare organizations to enhance patient outcomes, prevent diseases, and develop personalized treatment plans based on individual patient needs. Healthcare analytics play a crucial role in population health management, enabling healthcare providers to identify and address health disparities, monitor disease outbreaks, and implement preventive interventions on a larger scale. Healthcare analytics contributes to regulatory compliance by ensuring adherence to healthcare standards and guidelines, improving patient safety and quality of care. It also supports risk management and fraud detection by identifying anomalies and irregularities in billing and claim data.

    The Role of Data Analytics in Preventing Human Error and Securing Sensitive Information

    Human error is a major cause of preventable waste in healthcare, leading to significant costs and risks. Recent research estimates that mistakes such as incorrect tests, wrong prescriptions, or errors in patient records can cost US healthcare organizations up to $300 billion annually.

    In the UK, the NHS has reported around 237 million prescription errors each year as of 2020, with 28% of these being avoidable. These errors not only pose serious risks to patient safety but also have substantial financial impacts. They contribute to approximately 1,700 deaths and cost the NHS around £98.5 million annually.

    Data analytics offers a powerful solution to address these issues. By analyzing prescription patterns, procedures, and dosage ranges, analytics can help identify and prevent human errors. For example, it can predict which demographics might be at higher risk of addiction to certain medications, allowing for better-informed prescription practices that can save lives and reduce costs.

    Predictive analytics also plays a crucial role in preventing data breaches caused by human error. Studies indicate that 93% of US healthcare organizations have faced multiple cybersecurity breaches in the past three years. To combat this, many organizations are leveraging analytics to monitor changes in network traffic and behavior, predicting potential vulnerabilities. This helps keep sensitive data and electronic health records (EHRs) secure and protected.

    Healthcare Analytics Advancements Enable Tracking Daily Routines Effectively

    Healthcare is super high-tech, with remarkable technologies and digital tools popping up everywhere. You know those old paper charts your doctor used to keep? They’ve gone digital, becoming Electronic Health Records (EHRs). These EHRs hold all sorts of details about your medical history, like what illness you’ve had, what medicines you take, and even your lab test results.

    For instance,

    • In January 2021, Optum, Inc. partnered with Change Healthcare to enhance its technology-driven healthcare platform. Both firms offer consumers data analytics solutions, software, and advanced technology platforms for healthcare.

    But wait, there’s more! Have you seen those fancy watches people wear that can track their steps and heartbeats? Those are called wearable devices. They keep tabs on things like how much you move, how well you sleep, and even your blood sugar level, and all of that info can be sent straight to your doctor!

    Healthcare Analytics Market Companies

    • Optum Inc.
    • McKesson Corporation
    • Elsevier
    • Medeanalytics Inc.
    • Francisco Partners (IBM)
    • Allscripts Healthcare Solutions Inc.
    • Cerner Corporation
    • IQVIA
    • Oracle
    • SAS Institute, Inc.

    Healthcare Analytics Market Segments

    By Component

    • Software
    • Services
    • Hardware

    By Type

    • Descriptive
    • Predictive
    • Prescriptive

    By Application

    • Clinical
    • Financial
    • Operational & Administrative

    By Delivery Mode

    • Web Hosted
    • Cloud-based
    • On-premises

    By End User

    • Life Science Companies
    • Healthcare Payers
    • Healthcare Providers

    By Geography

    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

    Explore in-depth: https://www.healthcarewebwire.com/us-home-infusion-therapy-top-companies/ 

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/healthcare-analytics-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5141

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Parkinson’s Disease Diagnosis and Treatment Market Size Reach at USD 14.36 Billion by 2032

    The Parkinson’s disease diagnosis and treatment market size is estimated to grow from USD 6.32 billion in 2023 to reach around USD 14.36 billion by 2032, registering at a 8.9% of CAGR between 2024 and 2032.

    Parkinson's Disease Diagnosis and Treatment Market Size 2023 - 2032

    Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5142 

    Report Highlights:

    • Medications exhibited the contribution to the market with a 40% market share in 2023.
    • North America dominated with a 38% market share in 2023.
    • Asia Pacific is projected to be the fastest-growing market with a 7.0% CAGR over the forecast period.

    According to Parkinson’s News Today, about 41 out of every 100,000 people in their 40s are affected by Parkinson’s disease. This number increases to more than 1,900 out of every 100,000 for people in their 80s and 90s. Parkinson’s is the second most common neurodegenerative disorder, after Alzheimer’s disease. Right now, there’s no cure for Parkinson’s, and people with the condition need lifelong medication support.

    Parkinson’s disease is a neurological disorder characterized by involuntary movements such as tremors, stiffness, and difficulty with coordination. Symptoms usually develop gradually and worsen over time, affecting mobility, speech, and cognition. While the exact cause is unclear, research suggests a combination of genetic and environmental factors may contribute to the disease’s onset. Parkinson’s primarily affects the basal ganglia in the brain, leading to a decrease in dopamine production and subsequent movement problems. Despite ongoing research, the exact reasons for nerve cell death in Parkinson’s remain unknown.

    Parkinson’s has four major symptoms:

    • Tremors in the arms, legs, jaw or hands, head
    • Muscle stiffness
    • The slow movement
    • Diminished balance and coordination, can lead to falls

    Parkinson’s Disease Progression Can Be Defined in Stages

    There is a lot of interest in finding a treatment that will help slow the progression of Parkinson’s disease. These are known as neuroprotective or disease-modifying drugs. The idea is based on the notion that dopamine-producing neurons can be protected from premature death and dopamine depletion.

    At this point, no treatment is neuroprotective. Numerous treatments have been investigated, including MAO-B inhibitors, dopamine agonists, coenzyme Q10, and vitamin E. There is insufficient evidence to conclude that these therapies are beneficial, and they are not currently recommended to slow the Parkinson’s disease. Several clinical trials are being conducted to identify disease-modifying drugs.

    • In March 2022, Neuron23 secured $100 million in funding to further develop a therapy for Parkinson’s disease. The company plans to begin trials of NEU-723, a potential treatment for Parkinson’s, by the end of this year.
    • Based on a research study, the direct yearly medical expenses for each Parkinson’s disease patient in the U.S. are estimated to range from $10,043 to $12,491. Among these costs, prescription medications make up about 14-22%. Thanks to beneficial healthcare policies and reimbursement systems in developed nations like the U.S., the overall financial strain on individual patients has lessened.

    It’s really important to find out if someone has Parkinson’s early and give them the right treatment. This can help them manage their symptoms better and have a better quality of life.

    The Occurrence of Parkinson’s Disease is on the Rise Globally

    Parkinson’s disease (PD) is a condition that affects the brain and causes problems with movement, like shaking, stiffness, and slow movements. It’s becoming more common worldwide, especially in places where people are living longer lives. As more people get older, the number of those diagnosed with PD goes up.

    For instance,

    • According to a UN report, in 2020, there were around 727 million people who were 65 years old or older worldwide. This number is expected to double by 2050, reaching over 1.5 billion globally. As the number of older people increases, so does the prevalence of Parkinson’s disease.
    • Close to one million individuals in the United States are currently diagnosed with Parkinson’s disease (PD). Projections suggest that this figure will increase to 1.2 million by the year 2030. Parkinson’s stands as the second most prevalent neurodegenerative condition in the country, following Alzheimer’s disease.
    • Parkinson’s disease becomes more common as people get older, but about four percent of those diagnosed with PD are under 50 years old.
    • Men are 1.5 times more likely to have Parkinson’s disease compared to women.

    With more people getting Parkinson’s, there’s a bigger need for tools to help doctors find out if someone has it. These tools include things like scans and tests that can see inside the brain to spot signs of PD. When PD is detected early, doctors can start treatment sooner, which can help manage symptoms better and improve quality of life.

    Alongside diagnosis, there’s also a growing demand for treatments. Medicines that help control PD symptoms are becoming more important. These drugs can help reduce shaking, stiffness, and other issues caused by Parkinson’s, allowing people to live more comfortably.

    But it’s not just about medicines. As Parkinson’s progresses, people often need additional support. This includes therapies like physical therapy to keep muscles strong and occupational therapy to assist with everyday tasks. With more attention on Parkinson’s disease, there’s also more focus on research. Scientists are working hard to understand the disease better and develop new treatments. This research leads to discoveries that can improve the lives of those with PD.

    Deep Brain Stimulation Can Help Tremors and Make Movements Better for Individuals with Parkinson’s Disease

    Advancements in medical technology, such as deep brain stimulation (DBS) and infusion therapies, are aiding individuals with Parkinson’s disease (PD) by offering innovative treatment options. Deep brain stimulation involves implanting tiny electric wires in the brain to manage PD symptoms, while infusion therapies deliver medication directly into the body. These advancements contribute to improving patient care. The total cost of Parkinson’s disease in the United States, covering treatment expenses, social security aid, and lost income, is estimated to be around $52 billion annually.

    These innovations are a big deal because they expand the choices for treating PD. Before, there weren’t as many options, but now doctors and patients have more to choose from. This means better outcomes for patients – their symptoms can be managed more effectively, helping them feel better and live more comfortably.

    For instance,

    • DBS can reduce tremors and improve movement for people with PD. It’s like turning down the volume on the symptoms.

    And infusion therapies can provide a steady flow of medication, ensuring that patients get the right amount at the right time. Because these treatments work so well, more people want them. This creates a bigger market for companies that make these devices and therapies. They can sell more products, which means they can invest more in research and make even better treatments in the future.

    New Treatments Offer More Ways to Manage Parkinson’s Symptoms and Improve Quality of Life

    A study supported by the Parkinson’s Foundation in 2022 found that around 90,000 individuals receive a diagnosis of Parkinson’s disease in the United States every year. This marks a significant 50% rise from the earlier estimated figure of 60,000 diagnoses per year. Advancements in treating Parkinson’s disease (PD) are making a big impact on the market for PD diagnosis and treatment. Imagine you have a toolbox, and every time you find a new tool that works better, more people want to use it. That’s what’s happening with PD treatments. Infusion therapy, which delivers medicine directly into the body. These treatments offer new options for managing PD symptoms and improving quality of life.

    • In December 2021, a study involving 500 patients found that monoamine oxidase type B (MAO-B) inhibitors were more effective than catechol-O-methyltransferase (COMT) inhibitors in treating Parkinson’s symptoms that were not adequately controlled by levodopa.
    • The American Parkinson’s Disease Association (APDA) says there are four FDA-approved medicines called Dopamine Agonists for treating Parkinson’s disease in the U.S. These are Requip (ropinirole), Mirapex (pramipexole), Apokyn (apomorphine), and Neupro (rotigotine). Ropinirole and Pramipexole come in both long-acting and regular forms. Apomorphine is given through a vein injection and works quickly within 10 minutes in emergencies. So, if new medicines get approved for treating Parkinson’s, it will also help this group of medicines to grow.

    As more effective treatments become available, more people are seeking help. This increased demand for treatment options is driving growth in the PD market. Companies that make these treatments can sell more products and invest more in research to make even better treatments in the future.

    But it’s not just about treatments – better diagnosis tools are also making a difference. When doctors can identify PD earlier, they can start treatment sooner, which can slow down the progression of the disease and improve outcomes for patients.

    Difficulty in Early Diagnosis

    Diagnosing Parkinson’s disease early on can be tough because its symptoms aren’t always obvious and can resemble those of other health problems. Sometimes, individuals may not even realize they have Parkinson’s because the signs are subtle. This makes it hard for doctors to identify the disease quickly and start the right treatment. It’s like trying to find the right answer in a big book with lots of similar-looking pages – you need time to carefully examine each one to find the correct information. Similarly, doctors need time and specific tests to carefully study the symptoms and confirm if it’s Parkinson’s. Getting an early diagnosis is important because it lets doctors begin treatment sooner. Starting treatment early can help manage symptoms more effectively and improve the person’s quality of life.

    Geographical Landscape

    North America is home to leading pharmaceutical companies, biotechnology firms, and academic research institutions that are actively engaged in developing new therapies, diagnostic tools, and disease-modifying treatments for Parkinson’s disease. North America has a significant aging population, with a large proportion of individuals aged 65 and older. As PD is more common in older adults, this demographic trend contributes to the prevalence of the disease in the region. The regulatory landscape in North America, particularly in the United States and Canada, plays a crucial role in shaping the market for PD diagnosis and treatment. Approval processes for new drugs, medical devices, and treatment modalities impact market entry and commercialization strategies.

    The Asia-Pacific region is home to a diverse population, including both rapidly aging populations in countries like Japan and South Korea and younger populations in countries like India and Indonesia. The increasing prevalence of Parkinson’s disease, particularly in aging populations, drives demand for diagnosis and treatment options. Research and development activities in Parkinson’s disease diagnosis and treatment are gaining traction in the Asia-Pacific region, with academic institutions, healthcare organizations, and pharmaceutical companies collaborating to address unmet medical needs and develop innovative solutions.

    Competitive Landscape

    The competitive landscape for Parkinson’s disease diagnosis and treatment market is like a race among different companies. Each company tries to offer the best products and services to attract patients and healthcare providers. They compete by developing new medications, diagnostic tools, and treatment methods. Some companies may focus on affordability, while others emphasize innovation. It’s a dynamic environment where companies strive to stay ahead by offering effective solutions and staying up-to-date with advancements in the field.

    Recent Developments

    • In March 2022, Vyant Bio, Inc., a pioneering biotech firm dedicated to revolutionizing drug discovery for challenging neurological conditions, partnered with OrganoTherapeutics, a company specializing in personalized organoids mimicking Parkinson’s Disease (PD) symptoms, to collaborate on accelerating drug discovery efforts for treating PD.
    • In May 2020, Kynmobi, developed by Sunovion Pharmaceuticals Inc., received approval from the U.S. FDA for the treatment of off-episodes in individuals with Parkinson’s Disease (PD).
    • In January 2022, BlueRock Therapeutics initiated the initial administration of DA01 (dopaminergic neurons) to individuals with advanced Parkinson’s Disease (PD) in Canada. The expected successful conclusion of the trial and subsequent approval of the product are projected to stimulate growth in the region in the upcoming forecast period.

    Parkinson’s Disease Diagnosis and Treatment Market Companies

    • Siemens Healthineers AG
    • Abbott Laboratories
    • General Electric Company
    • AbbVie
    • Merck & Co.
    • Pfizer
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharma
    • Novartis AG
    • Cerevel Therapeutics

    Parkinson’s Disease Diagnosis and Treatment Market Segments

    By Diagnosis

    • Imaging Tests
    • Blood Tests
    • Other Tests

    By Treatment

    • Medications
      • Carbidopa-levodopa
      • Dopamine Agonists
      • MAO-B Inhibitors
      • COMT Inhibitors
      • Anticholinergics
      • Others
    • Deep Brain Stimulation
    • Other Treatments

    By Geography

    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

    Explore in-depth : https://www.healthcarewebwire.com/us-home-infusion-therapy-news/

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/parkinsons-disease-diagnosis-and-treatment-market-sizing 

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5142

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Respiratory Drugs Market Size Rise at USD 28.11 Billion by 2032

    The respiratory drugs market size is estimated to grow from 16.57 billion in 2023 to reach around USD 28.11 billion by 2032, registering a CAGR of 5.8% between 2024 and 2032.

    Respiratory Drugs Market Size 2023 - 2032

    Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5137

    Report Highlights

    • Chronic Obstructive Pulmonary Disease (COPD) being the most prevalent respiratory disorder captured the largest 36% market share in 2023.
    • Bronchodilators recorded a dominant 40% market share in 2023.
    • Hospital pharmacies were the top distributors among all in 2023.

    In 2021, the CDC reported 142,342 deaths from lower chronic respiratory disease in the United States, highlighting the urgent need for innovative treatment approaches. This significant toll underscores the demand for advancements in managing these conditions effectively.

    Respiratory disorders cover a broad range of issues affecting the system responsible for breathing, including the lungs, airways, and respiratory muscles. When these parts of the body encounter problems, it can make breathing difficult and lead to various symptoms like coughing, wheezing, shortness of breath, and chest tightness. There are several respiratory disorders, each with its characteristics and causes. Obstructive disorders, such as asthma and chronic obstructive pulmonary disease (COPD), involve blockages in the airways, hindering airflow in and out of the lungs. Restrictive disorders, like pulmonary fibrosis, limit the lungs’ ability to expand fully, making breathing hard.

    • In 2020, the National Institutes of Health undertook a comprehensive investigation involving 255,857 patients to examine the effectiveness of inhaled treatments, including triple therapy, for Chronic Obstructive Pulmonary Disease (COPD).

    Child and Adult Asthma Prevalance By Age and Sex in U.S. 2021

    As more people are found to have respiratory disorders, there’s a growing demand for treatments that can ease symptoms and enhance life quality. Effective treatments can reduce symptoms, prevent complications, and support active lifestyles despite the condition. According to the CDC, diabetes mellitus was the most common medical risk factor for TB illness in 2021 (23.9%), while 4.2% of TB patients were also diagnosed with HIV. Additionally, advancements in medical research are leading to new treatments like bronchodilators and corticosteroids for symptom relief, targeted therapies for lung cancer and pulmonary rehabilitation programs to boost lung function and overall health.

    Infections caused by viruses, bacteria, fungi, or other pathogens can also affect the respiratory system, leading to illnesses like the common cold, influenza, pneumonia, tuberculosis, and respiratory syncytial virus (RSV) infection. Inflammatory disorders, including bronchitis and allergic rhinitis, involve airways or lung tissue inflammation, resulting in breathing difficulties and discomfort. Neoplastic disorders, like lung cancer, involve abnormal cell growth in the respiratory system, which can lead to serious health complications.

    Respiratory disorders can stem from various factors, including genetic predisposition, environmental factors like pollution and exposure to tobacco smoke, infections, lifestyle choices such as smoking and poor nutrition, and occupational exposures to dust, chemicals, or fumes. It’s crucial to address these underlying causes to manage respiratory conditions effectively.

    • In February 2021, Royal Philips N.V. finalized its acquisition of BioTelemetry, Inc., which will enhance its cancer diagnostics segment.

    Appropriate treatment is essential for managing respiratory disorders and improving patients’ quality of life. Treatment aims to alleviate symptoms, slow disease progression, prevent complications, improve lung function, and enhance long-term outcomes. This may involve medication such as bronchodilators, corticosteroids, antibiotics, lifestyle modifications, oxygen therapy, and other interventions tailored to the individual’s needs.

    Respiratory disorders can significantly impact daily life, but understanding their types, causes, and the importance of appropriate treatment is critical to managing these conditions effectively. Early diagnosis, lifestyle changes, and medical interventions are crucial in optimizing respiratory health and well-being.

    Respiratory Drugs Market Companies

    • GlaxoSmithKline Plc
    • AstraZeneca Plc
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Mylan Pharmaceuticals Inc.
    • Sun Pharmaceutical Industries Ltd.

    Respiratory Drugs Market Segments

    By Disease Type

    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Lung Cancer
    • Respiratory Tract Infection
    • Allergic Rhinitis
    • Cystic Fibrosis (CF)
    • Others

    By Drug Class

    • Bronchodilators
    • Corticosteroids
    • Combination Drugs
    • Antibiotics
    • Target Therapy
    • Immunotherapy
    • CFTR
    • Others

    By Route of Administration

    • Oral
    • Nasal
    • Injectable

    By Distribution Channel

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    By Geography

    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

    Dig into: https://www.healthcarewebwire.com/ar-and-vr-in-healthcare-market/

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/respiratory-drugs-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5137

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Rheumatoid Arthritis Drugs Market Size Rise at USD 27.38 Billion by 2033

    The rheumatoid arthritis drugs market size achieved a value of USD 17.87 billion in 2023 with this trajectory, it is expected to reach USD 27.38 billion by 2033. Projected growth indicates a compound annual growth rate (CAGR) of 4.6% over the forecast period. 

    Rheumatoid Arthritis Drugs Market Size 2023 - 2033

    Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5122

    Due to the rising rheumatoid arthritis population, the CDC organized a program to help manage and improve the well-being of those with the condition. Between 2019 and 2021, about 24.2% of women and 17.9% of men in the United States were told by a doctor that they had arthritis.

    Rheumatoid arthritis is a type of arthritis that happens when your immune system mistakenly attacks the lining of your joints, called the synovium. This causes inflammation, pain, stiffness, and swelling in the affected joints. Over time, this inflammation can damage the joints and lead to deformities or loss of function. Rheumatoid arthritis commonly affects the hands, wrists, and knees but can also affect other joints. It’s a chronic condition, meaning it usually lasts a long time and requires ongoing management to control symptoms and prevent joint damage.

    Rheumatoid arthritis is a progressive disease, meaning it can get worse over time if not treated. It can damage your joints, making them deformed and difficult to move. If detected early and managed correctly, the worsening of the disease can often be slowed down or stopped. We’re not sure what causes rheumatoid arthritis, but things like your genes, environment, and hormones might play a role. Women tend to get rheumatoid arthritis more than men. To diagnose rheumatoid arthritis, doctors will ask about your symptoms, examine your joints, and do some blood tests and imaging tests like X-rays or ultrasound to see how much damage there is.

    Recent Developments

    • In July 2023, Biocon Biologics Ltd, a part of Biocon Ltd, said they had made HULIO (adalimumab fijp) injection available in the US. It’s similar to Humira (adalimumab) and is used to treat rheumatoid arthritis.
    • In February 2022, Pfizer Inc. shared that the US Food and Drug Administration (FDA) agreed to review their application for ABRILADA (adalimumab-afib). They want it to be recognized as a biosimilar drug to Humira (adalimumab) that can be swapped with the original.
    • In February 2022, Biogen Inc. and Xbrane Biopharma AB collaborated to develop, make, and sell Xcimzane. This drug is still in the testing phase but aims to be like CIMZIA (certolizumab pegol), another medicine used for rheumatoid arthritis.

    Market Players

    Market Segments

    By Drug Type

    • Pharmaceuticals
      • NSAIDs
      • Analgesics
      • DMARDs
      • Glucocorticoids
    • Biopharmaceuticals
      • Biologics
        • TNF-α Antagonists
        • T-cell Inhibitors
        • CD20 Antigen
        • JAK Inhibitors
        • Anti-IL6 Biologics
      • Biosimilars
        • CD20 Antigen
        • TNF-α Antagonists

    By Distribution Channel

    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

    By Route of Administration

    • Oral
    • Parenteral
    • Topical

    By Geography

    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa

    Explore in-depth: https://www.healthcarewebwire.com/cell-therapy-manufacturing-market/

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/rheumatoid-arthritis-drugs-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5122

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Ambulatory Surgical Center Market Size (USD 167.1 Bn by 2032) Report

    The ambulatory surgical centers market accounted for USD 94.57 billion in 2022 and is predicted to increase to USD 167.1 billion by 2032 and is poised to grow at a CAGR of 5.66% from 2023 to 2032.

    Ambulatory Surgical Centers Market Size 2023 - 2032

    Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5021

    Ambulatory surgery centers (ASCs) are specialized medical facilities that offer outpatient surgical services. Outpatient refers to a patient who is not admitted to a hospital and can leave on the same day of their surgery. Before the advent of ambulatory surgery centers in the 1970s, nearly all surgical procedures were conducted in hospital settings. While hospitals can be relied on to provide quality treatment, patients seeking elective surgery face several challenges, including scheduling delays and restricted operating room availability. ASCs have been a popular alternative to inpatient hospital settings in recent decades due to their flexible scheduling options, calmer and more comfortable environments, and cheaper prices.

    Ambulatory Surgical Center Market Companies

    • Cerner Corporation
    • Allscripts Healthcare Solutions Inc.
    • McKesson Corporation
    • Medical Information Technology Inc.
    • Advanced Data Systems Corporation
    • Surgical Information Systems
    • NextGen Healthcare
    • Philips Healthcare
    • Epic Systems Corporation
    • GE Healthcare

    Value and Impact of Ambulatory Surgery Centers (ASCs) on Outpatient Care

    Ambulatory Surgery Centers (ASCs) offer significant value through high-quality outcomes and lower-cost care, making them the optimal choice for many healthcare procedures for the right patients at the right price. Currently, over 80% of surgeries are conducted in an outpatient setting, largely due to the innovations driven by ASCs that have revolutionized outpatient surgery. These advancements in technology and techniques have enhanced the safety and comfort of outpatient procedures. With the aging population in America, particularly the baby boomers, the demand for the services provided by surgery centers is on the rise.

    Presently, more than 49 million people, or 15% of the U.S. population, are 65 or older, and this demographic is projected to grow to 24% by 2060. ASCs also contribute to reducing healthcare expenses for patients, insurers, and Medicare, achieving a one-year savings of $42.2 billion in healthcare spending and creating $4.2 billion in annual Medicare savings by offering an alternative to traditional hospital settings.

    How AI Integration is Revolutionizing the Ambulatory Surgical Center Market?

    The integration of Artificial Intelligence (AI) is set to significantly enhance growth in the Ambulatory Surgical Center (ASC) market. AI technologies, such as machine learning and data analytics, streamline various aspects of surgical operations and patient care. One of the primary benefits is improved diagnostic accuracy; AI algorithms can analyze medical imaging with exceptional precision, aiding in quicker and more accurate diagnoses. Additionally, AI-driven predictive analytics assist in anticipating patient needs and optimizing surgical schedules, which enhances operational efficiency and reduces waiting times.

    AI also enhances patient outcomes through personalized treatment plans. By analyzing vast datasets, AI can tailor interventions to individual patient profiles, potentially leading to better results and fewer complications. Furthermore, robotic-assisted surgeries, powered by AI, offer high precision and minimally invasive options, which contribute to faster recovery times and reduced hospital stays.

    Overall, AI integration in ASCs is driving innovation, improving efficiency, and enhancing patient care. This technological advancement is expected to spur market growth by attracting investments and meeting the increasing demand for advanced, high-quality surgical services.

    Factors Influencing the Ambulatory Surgical Center Industry

    The shift from surgical procedures in hospitals to ambulatory settings is the factor influencing the growth of the ACS industry. Over the last decade, the number of surgical procedures performed in ambulatory surgery facilities has increased significantly. Given the factors like as shorter stays, innovative technologies, cost-effective surgical procedures, and lower infection risks, a large number of patients select these healthcare facilities for various surgeries.

    Outpatient surgical volume in ambulatory surgical facilities, for instance, has increased over the last decade, according to data from the Medicare Payment Advisory Commission and VMG Health. ASCs performed nearly 60% of outpatient procedures in 2019, compared to 48% in 2010. Ambulatory surgery centers (ASCs) are redefining healthcare delivery as well as the medical device and equipment industry. ASCs can offer surgical treatments at rates 35% to 50% lower than hospitals by focusing on standard, lower-risk procedures in a more convenient location. This benefits the US healthcare system an estimated $40 billion per year while also influencing ASC growth. In 2018, 5,700 ASCs in the United States completed 23 million procedures and earned $35 billion in revenue.

    Broad industry trends are driving the growth of ASCs, the first of which was established in 1970. A consistent increase in healthcare spending has put a strain on costs and margins across the industry, promoting a shift to outpatient treatment. Payers are assisting in the shift of procedures to ASCs by lowering provider reimbursements for hospitals and lowering patient copayments for outpatient procedures.

    Increasing government investments toward developing new ambulatory settings are expected to drive industry growth. Moreover, Due to weakened immunity and aging, the elderly population is more vulnerable to infectious and chronic diseases. Chronic diseases are a leading cause of disability and mortality in both developing and developed countries. This indicates a critical need for technologically advanced ambulatory surgical centers capable of providing superior patient care.

    Restraining Factors of the Ambulatory Surgical Center Industry

    The high costs associated with advanced medical devices are a major factor hindering the growth of the ambulatory surgical center industry. The equipment required for complex surgical procedures is complex and expensive, with high costs for procurement, installation, and maintenance. Smaller healthcare facilities struggle to meet the growing demand for sophisticated technologies in neurosurgery, cardiovascular surgery, interventional cardiology, and orthopedic surgery. In the United States, a cutting-edge portable digital X-ray unit costs more than US$ 100,000 on average. Even basic medical equipment, such as an operating table, can cost more than US$ 50,000.

    Over the last decade, a sizable portion of the patient population in the United States has indicated a preference for having surgical procedures performed at outpatient surgery centers. However, the market’s expansion is expected to be hampered over the aforementioned term by several drawbacks associated with ASCs. Among these disadvantages are the lack of overnight accommodations, the possibility of difficulties and crises during some surgical procedures, and the lack of any contingency plans. If complications or issues arise during a surgical procedure, patients may be transferred from ambulatory surgical centers to hospitals in the surrounding area. As a result, some patients prefer to have their surgical procedures done in hospitals. According to a research report distributed by the National Center for Biotechnology Information (NCBI) in 2017, the rate of complications and adverse events as a result of orthopedic procedures performed at ASCs was between 0.05 percent and 20.0 percent.

    The most common complications during surgical procedures include pain and nausea, poor recovery, and infection. The industry’s growth may be hampered by these disadvantages.

    Opportunity in the ACS Industry

    One of the key drivers of industry growth is reimbursement. Favorable reimbursement policies are driving the Centers for Medicare & Medicaid Services (CMS) to expand the list of surgical procedures that are permitted in ASCs. Rising commercial payer initiatives to encourage physicians to perform various surgical procedures in these facilities are expected to fuel the industry in future payers. Furthermore, CMS is constantly reviewing the complications associated with surgical procedures, thereby improving patient safety when undergoing surgical procedures. For instance, according to Advisory Board CMS planned to review 38 procedures such as spine surgery, and lumbar, and cervical spinal fusions to determine if they are safely performed in ambulatory settings in September 2018.

    Payers’ intense focus on the safety of surgical procedures in these healthcare facilities will attract a larger patient pool throughout the United States. Thus, the favorable reimbursement scenario for procedures performed in ambulatory settings, combined with a greater emphasis on procedure safety, is expected to propel industry growth in the future.

    COVID-19 & ACS Industry

    The coronavirus pandemic had a significant impact on the industry of ambulatory surgical centers. COVID-19 ushered in significant operational changes in how services should be delivered. The demand for ambulatory surgical care increased at a faster rate as the incidence of covid-19 and other infectious diseases increased. The availability of these healthcare services is greatly impacted by increased demand. Given the increasing number of COVID-19 patients and the growing geriatric population, who are more susceptible to infection, it was advisable to prefer remote healthcare, which increased the demand for ambulatory surgical centers.

    The increasing number of patients suffering from chronic diseases, as well as the growing sedentary lifestyle and geriatric population, has increased the demand for ambulatory surgical centers. The supply chain was not spared as the world came to a halt for nearly six months due to the emergence of COVID-19. To stop the spread of the disease, governments around the world imposed a total lockdown. As a result of the border closures, the supply chain and third-party logistics came to a halt. Despite the high demand for ambulatory surgical care services, availability was hampered by supply chain disruptions, trade restrictions, and travel restrictions. The availability of raw materials was also impacted, limiting device production. Due to limited production, supply bottlenecks were anticipated. Notwithstanding, some industries overcame the obstacles and experienced rapid growth.

    Segmental Outlook

    The ambulatory surgical center is segmented based on the type of center, ownership, and application. Based on the type of center, the industry is further segmented into single-specialty and multispecialty. The single-specialty segment dominates the industry in 2022 and is anticipated to continue to show similar trends in the coming years. The growing incidence and prevalence of ophthalmic disorders, as well as the strong presence of single-specialty ambulatory surgical centers, account for the dominance of single-specialty settings. During the forecast period, the multi-specialty segment is expected to grow at a significant CAGR. The increasing number of surgical procedures in ophthalmology, gastroenterology, and pain management is expected to boost multi-specialty setting revenue in the coming years.

    Based on ownership, the ACS industry is further segmented into physician-owned, hospital-owned, and corporate-owned. The physician-owned segment accounted for the largest share in 2022 and is expected to expand at a substantial CAGR during the forecast time. Physician-owned ambulatory settings are the most common, with doctors owning 100% of the stock. The segment’s large share is also attributed to factors such as physicians’ convenience in scheduling surgical procedures, which has led to an increased preference for this type of ownership in the United States.
    Ambulatory Surgical Centers Market Revenue Share, By Ownership, 2022 (%)

    In 2022, the hospital-owned segment has the second-highest market share and is expected to grow at a significant CAGR during the forecast period. Increased employment of physician-owned practices by hospital-owned practices is expected to boost hospital-owned center revenue in the future. In the corporate-owned segment, I anticipated expanding at the highest CAGR during the forecast period. This segment’s rapid growth can be attributed to the increasing focus of management companies and physicians on the formation of a common joint venture. As partnerships between corporate firms and physicians continue to emerge, the ownership model is expected to boost the revenue of corporate-owned centers in the coming years.

    Ambulatory Surgical Centers Market Revenue Share, By Application, 2022 (%)

    Based on application, the industry is further segmented into ophthalmology, orthopedics, gastroenterology, pain management/spinal injections, plastic surgery, and others. In 2022, the gastroenterology segment dominated the ambulatory surgical center industry, accounting for 35% of total revenue. Given its global reach, the gastroenterology segment accounted for the largest share of the global ambulatory surgical center industry. Plastic surgery, on the other hand, is expected to grow at the fastest rate in the coming years. Patients’ preferences for nonsurgical and minimally invasive surgeries are expected to rise, assisting the plastic surgery segment to expand rapidly.

    North America to Soar Ambulatory Surgical Center Industry

    North America dominated the ambulatory surgical center market in 2022, with a revenue share of more than 48%. Increased government support for primary care services and expanded outpatient coverage are major factors driving the growth of the ambulatory surgical center market in North America.

    Ambulatory Surgical Centers Market Revenue Share, By Region, 2022 (%)In contrast, Asia-Pacific is expected to grow at the fastest rate during the forecast period. Outpatient facility expansion has resulted from rising healthcare expenditures due to an increase in the prevalence of chronic diseases, an aging population, high healthcare expenditures, and rising hospitalization rates. All of the aforementioned factors are propelling the region’s ambulatory surgical center industry forward.

    Competitive Landscape 

    The rise of the healthcare sector is fueling demand in the ambulatory surgical center industry, which is exacerbated by an increase in research on service portfolios in mobile operative systems. The healthcare industry’s major players are investing in research and development to build mobile surgery centers. Businesses primarily increase revenue through acquisitions, mergers, collaborations, and product portfolio enhancement through extensive research and development. To gain a significant market position and maintain industry rivalry in the ambulatory surgical center industry, the major market players are employing a variety of inorganic and organic growth strategies.

    Key Developments

    • GE Healthcare released Edison Datalogue. n 2019, MEDITECH and Google collaborated to make electronic health record data available on the Google Cloud Platform. This improved patient data security as well as scalability and interoperability.
    • Epic Systems and Teledoc Health collaborated in 2019 to integrate Teledoc’s virtual care platform with Epic’s App Orchard, enabling the company to conduct telehealth video visits.
    • Terveystalo purchased Attendo’s Finnish healthcare services in December 2018, with the combined operations set to begin in January 2019. This acquisition has helped the company establish a stronger foothold in the Finnish market.
    • In May 2018, AMSURG announced the acquisition of Horizon Eye & LASIK Center to add ophthalmology to its network of ambulatory surgery centers for improved patient care.
    • In June 2016, AmSurg Corporation announced a merger with Envision Healthcare Holdings Inc., a company that provides healthcare services with tremendous opportunities, fair treatment, and innovations that benefit patients.

    Read Also: https://www.healthcarewebwire.com/cell-therapy-manufacturing-market/

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/factors-influencing-the-ambulatory-surgical-center-industry

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5021

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare